FDA Classifies Simple SARS-CoV-2 Point-of-Care Test as Class II Device

The Food and Drug Administration has officially classified a specific type of rapid COVID-19 test into Class II. This classification covers simple point-of-care devices that directly detect viral targets from clinical specimens in near-patient settings, meaning they are used by healthcare professionals outside of central laboratories without complex sample manipulation.

Why it matters: This is primarily an administrative update that clarifies how certain rapid tests are regulated moving forward. It reduces the regulatory burden for manufacturers of these specific types of tests, potentially encouraging more innovation and competition in this niche. For consumers, it confirms that these near-patient tests meet established safety standards without requiring the highest level of scrutiny reserved for implantable or life-support devices.

Who it affects

• Medical device manufacturers, specifically those producing simple point-of-care SARS-CoV-2 diagnostic tools

---

This final order was issued by the Food and Drug Administration under the Department of Health and Human Services; readers should consult the original Federal Register document for full details on special controls and labeling requirements.

Agency: Health and Human Services Department, Food and Drug Administration
Source: Federal Register — read the official document